TUSTIN, CA -- (Marketwired) -- 08/06/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that members of its management team will be presenting at the following conferences:

Wedbush Securities Life Sciences Management Access Conference
Date: Tuesday, August 13, 2013
Time: 4:15 PM Eastern Daylight Time
Location: Le Parker Meridien Hotel, New York, New York
Presenter: Steven W. King, president and chief executive officer

Cambridge Healthtech Institute's Immunomodulatory Therapeutic Antibodies for Cancer Conference
Date: Wednesday, August 14, 2013
Time: 3:00 PM Eastern Daylight Time
Location: Boston, Massachusetts
Presenter: Jeffrey T. Hutchins, Ph.D. vice president, preclinical research

Peregrine's presentation at the Wedbush conference will be webcast live and available for replay until August 27, 2013 at: http://ir.peregrineinc.com/events.cfm

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media